Jasper Therapeutics Inc (JSPRW)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Jasper Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Jasper Therapeutics Inc (JSPRW) has returned -45.39% so far this year and -84.69% over the past 12 months.

Based on dividend-adjusted daily data since Jan 10, 2020, JSPRW's average daily return is +0.66%, while the average monthly return is +3.56%. At this rate, your investment would double in approximately 1.7 years.

Historically, 44% of months were positive and 56% were negative. The best month was Jan 2023 with a return of +383.3%, while the worst month was Dec 2025 at -70.7%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 7 months.

On a daily basis, JSPRW closed higher 32% of trading days. The best single day was Jan 3, 2023 with a return of +407.3%, while the worst single day was Dec 31, 2025 at -64.3%.

Jasper Therapeutics Inc has an annualized alpha of 389.33%, beta of 0.37, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since January 13, 2020.

• This stock participated in 256.46% of S&P 500 Index downside but only 56.14% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.37 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

JSPRW ranks 19 for risk / return — in the bottom 19% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Jasper Therapeutics Inc (JSPRW) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Jasper Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Jasper Therapeutics Inc was 99.24%, occurring on Feb 23, 2026. The portfolio has not yet recovered.

The current Jasper Therapeutics Inc drawdown is 98.95%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Jasper Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Jasper Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.